[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594330":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":35,"sex":41,"minAge":42,"maxAge":7,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Regina Elena Cancer Institute","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Fabio Calabrò, Doctor","CONTACT","+39 0652666271","fabio.calabro@ifo.it",[15],{"facility":16,"status":17,"city":18,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"\"Regina Elena\" National Cancer Institute","RECRUITING","Rome","00144","Italy","IT",{"type":23,"coordinates":24},"Point",[25,26],12.51133,41.89193,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":12,"phoneExt":7,"email":13},"Fabio Calabrò",{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100594330","role-of-ttv-during-first-line-immunotherapy-treatment-in-patients-with-renal-cell-carcinoma-100594330",false,"NCT07018037","Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma","Pilot Study to Describe the Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma","TTV ccRCC","Inclusion Criteria:\n\n* Patients over 18 years of age;\n* Histological diagnosis of clear cell renal cell carcinoma;\n* Evidence of advanced or metastatic disease;\n* Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI);\n* Patients able to comply with the study procedures.\n* Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started.\n\nExclusion Criteria:\n\n* Previous neoplasms;\n* Previous antineoplastic treatments;\n* Previous steroid treatments;\n* Active viral infections (e.g., HCV, HIV, etc.);\n* Lack of autonomy in adhering to study procedures.","ALL","18 Years",{"count":44,"type":45},20,"ESTIMATED","OBSERVATIONAL","The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.",[49],"Renal Cell Carcinoma",[51],"Torquetenovirus (TVV)","2026-06-04",{"date":54,"type":55},"2026-06-05","ACTUAL",{"date":57,"type":55},"2025-01-29",{"date":59,"type":45},"2027-01-29",{"name":5,"class":6},1]